GSK acquires Siran Biotechnology for $1 billion to expand beyond weight-loss with siRNA therapy on May 12, 2026 acquisition muscle preservation Obesity Oligonucleotides RNA, Small Interfering SA030 Siran Biotechnology SmithKline Beecham weight-loss +
Metsera Reports Once-Monthly Amylin Analogue Matches GLP-1 Efficacy in Early Phase 1 Results on June 10, 2025 Amylin Clinical Trials Glucagon-Like Peptide 1 MET-233i Metsera Obesity once-monthly Phase 1 (qualifier value) weight-loss +